Surrozen, Inc./DE Investment Income, Amortization of Premium
Surrozen, Inc./DE (SRZN) reported Investment Income, Amortization of Premium of $108.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfPremium · last filed 2023-03-31
- Surrozen, Inc./DE investment income, amortization of premium for the quarter ending 2022-12-31 was -$162.00K, a 254.29% decline year-over-year.
- Surrozen, Inc./DE investment income, amortization of premium for the quarter ending 2022-09-30 was $35.00K.
- Surrozen, Inc./DE investment income, amortization of premium for the quarter ending 2022-06-30 was $119.00K.
- Surrozen, Inc./DE investment income, amortization of premium for the quarter ending 2022-03-31 was $116.00K.
- Surrozen, Inc./DE investment income, amortization of premium for fiscal 2022 was $108.00K, a 2.86% increase from fiscal 2021.
- Surrozen, Inc./DE investment income, amortization of premium for fiscal 2021 was $105.00K, a 10400.00% increase from fiscal 2020.
- Surrozen, Inc./DE investment income, amortization of premium for fiscal 2020 was $1.00K.
| Period end | Investment Income, Amortization of Premium 3 month | Investment Income, Amortization of Premium 6 month | Investment Income, Amortization of Premium 9 month | Investment Income, Amortization of Premium 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$127.00K derived: sum of 2 quarters · filed 2023-03-31 | -$8.00K derived: sum of 3 quarters · filed 2023-03-31 | $108.00K 10-K · filed 2023-03-31 |
| 2022-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $154.00K derived: sum of 2 quarters · filed 2022-11-14 | $270.00K 10-Q · filed 2022-11-14 | $375.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $235.00K 10-Q · filed 2022-08-11 | $340.00K derived: sum of 3 quarters · filed 2023-03-31 | $340.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-03-31 | $116.00K 10-Q · filed 2022-05-11 | $221.00K derived: sum of 2 quarters · filed 2023-03-31 | $221.00K derived: sum of 3 quarters · filed 2023-03-31 | $221.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $105.00K derived: sum of 2 quarters · filed 2023-03-31 | $105.00K derived: sum of 3 quarters · filed 2023-03-31 | $105.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $1.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |